Executive Summary
When a treatment course turns clinically complex and a family or insurer needs an independent,
evidence-based view, speed and credibility both matter. A second opinion is only as valuable as
the rigor behind it — the calibre of the reviewing expertise, the precision of the questions asked,
and the willingness to press treating teams for clarity rather than accept a narrative at face
value.
In April 2026, Prospera Global was engaged to coordinate an independent Medical Second
Opinion (SMO) for a 36-year-old patient managed at a renowned hospital in Dubai for
advanced, poorly differentiated gastric adenocarcinoma (signet ring type) diagnosed during
pregnancy. Her post-caesarean course was complicated by malignant bowel obstruction,
peritonitis, a suspected catheter-related infection, and a jejunal perforation requiring two
separate laparotomies — a case spanning obstetrics, surgical oncology, infectious disease, and
critical care simultaneously.
Prospera Global engaged its SMO advisory team of oncologists, structured five distinct clinical
queries spanning antenatal diagnosis, bowel obstruction management, perforation timing, line
related infection, and chemotherapy initiation under sepsis, and then ran two full rounds of
query-and-response engagement directly with the treating physicians in Dubai. Every clinical
claim made by the treating team was tested against the advisory team's independent findings
before the report was finalised, reviewed, and formally approved.
The result was a rigorously governed, multi-round Second Medical Opinion report — not a
single-pass document, but an iterative clinical dialogue that surfaced genuine areas of
disagreement on perforation management and chemotherapy timing, while still allowing both
sides of the clinical reasoning to be placed on record for the family and the insurer.
The Challenge
An SMO request is only straightforward when the underlying case is simple. This one was not.
This case combined an oncological emergency, an obstetric emergency, and a surgical
emergency within the same admission — and the second opinion needed to interrogate all three
without delaying the family's need for clarity.
The core challenges Prospera Global had to navigate simultaneously were:
-
Rare and aggressive oncology in pregnancy — Gastric adenocarcinoma (signet ring /
linitis plastica pattern) presenting during the third trimester is exceptionally uncommon,
with diagnostic and treatment pathways that are not well standardised.
-
Multi-specialty clinical scope — A credible opinion required expertise spanning
obstetrics, surgical oncology, gastrointestinal surgery, and infectious disease — not a
single specialist's narrow view.
-
Sequential surgical complications — Malignant bowel obstruction, ascitic and then
septic peritoneal collections, an initial non-diagnostic laparotomy, and a confirmed jejunal
perforation on a second laparotomy created a layered timeline that demanded careful
reconstruction.
-
Contested clinical judgment calls — Several decisions — conservative management of
suspected perforation, timing of chemotherapy initiation relative to sepsis, and the cause of
a rapid PICC-line infection — sat in genuinely debatable clinical territory rather than clear
protocol breaches.
-
Cross-border engagement — Prospera Global's SMO advisory team coordinated with a
treating team of four separate physicians at a renowned hospital in Dubai, requiring
structured, asynchronous coordination across time zones and institutions.
-
Need for a multi-round process — A single round of questions and answers was not
sufficient. Several treating-team responses raised new clinical detail that required a
second, more pointed round of scrutiny before the opinion could be considered complete.
Clinical Review Journey
The case was submitted for independent review on 19 April 2026. Prospera Global's SMO
advisory team examined the full clinical record — from antenatal presentation and caesarean
delivery at 33 weeks through malignant bowel obstruction, two laparotomies, a disputed PICC
line infection, and chemo-immunotherapy initiation — and issued the initial Second Medical
Opinion the same day, identifying five areas requiring the treating team's direct response.
In Round One, all four treating physicians at the renowned hospital in Dubai responded on
record: the obstetrician confirmed prompt diagnosis once symptoms emerged, the surgeon set
out the rationale for conservative management before the second laparotomy repaired a mid
jejunal perforation on 4 April, the infectious disease physician affirmed aseptic PICC insertion,
and the oncologist confirmed chemo-immunotherapy began once inflammatory markers were
improving. These responses were reviewed on 29 April 2026.
Because key questions remained open, the advisory team issued a second, more pointed
round: outstanding antenatal scan records were formally requested, the drain-culture findings
were re-examined against the conservative management decision, and the infection timeline
was challenged directly — a PICC site exuding pus within roughly two hours of placement was
characterised as clear evidence of septic contamination at insertion, regardless of a negative tip
culture. Both positions were placed on record, the second round was reviewed on 5 May 2026,
and the report was finalised for governance sign-off.
Value Delivered Through Prospera Global's SMO Coordination
Unlike the cost-table economics of an emergency GOP case, the value of a Second Medical
Opinion engagement is measured in clinical rigor, turnaround discipline, and the credibility of the
final document handed to the family and the insurer.
| Coordination Element |
What Prospera Global Delivered |
Result |
| SMO Advisory Team Engaged |
Prospera Global's SMO advisory team of oncologists, with deep GI-oncology expertise |
Case-matched senior review within days of request |
| Structured Query Rounds |
5 clinical questions spanning obstetrics, oncology, surgery and infection control |
Single consolidated, auditable report |
| Treating-Team Engagement |
Documented responses from 4 treating physicians in Dubai |
Full multidisciplinary participation secured |
| Iterative Review Cycles |
Two structured rounds of query and response (29 April; 5 May 2026) |
Each clinical point tested and clarified before sign-off |
| Independent Governance |
Reviewed by Dr. Sakshi Sharma; approved by Dr. Geeta Sadana |
Quality-controlled opinion, not a single-reviewer document |
Outcome
What began as a request to "review a complicated file" was developed into a structured, two
round, multi-specialist Second Medical Opinion that gave the family and the insurer a clinically
rigorous, independently governed view of a genuinely difficult case.
-
SMO advisory team engaged — Prospera Global's advisory team of oncologists, with
directly relevant GI-oncology expertise, conducted the independent review.
-
Five structured clinical questions resolved — Antenatal diagnosis, bowel obstruction
management, perforation management, PICC-line infection, and chemotherapy timing
were each independently assessed.
-
Two full review rounds completed — Reviewed on 29 April and again on 5 May 2026,
ensuring incomplete first-round answers did not stand unchallenged.
-
Four treating physicians engaged directly — Obstetric, surgical, infectious disease, and
oncology perspectives from the renowned hospital's treating team in Dubai were formally
documented.
-
Independent governance completed — The report was reviewed by experienced doctors
of Prospera Global — Dr. Sakshi Sharma — and finally approved by Dr. Geeta Sadana
(Director Medical Claims, Audit, & Training) prior to release.
-
Transparent, evidence-based conclusion delivered — Genuine areas of clinical
disagreement were preserved on record rather than glossed over, giving the family and
insurer a defensible, complete picture.
This case stands as a clear demonstration of what Prospera Global delivers when a second
opinion needs to be more than a formality — rare and aggressive pathology, multi-specialty
complexity, and contested clinical judgment calls, resolved through a rigorous, independently
governed review process that did not stop at the first round of answers.
Insurer Benefit: From Passive Payer to Informed Negotiator
Beyond clarifying the clinical picture for the family, the SMO changed the insurer's position with
the treating facility. Instead of settling the invoice on submission, the insurer paused payment
and entered direct negotiation with the hospital on the final cost of care — citing the advisory
team's findings on delayed perforation management, contentious chemotherapy timing under
sepsis, and the disputed PICC-line infection as specific, defensible grounds to challenge the
billed charges.
Value to the Insurer:
- Converted a routine claim payout into an evidence-based negotiation
- Gave the insurer specific clinical grounds — not just administrative pushback — to question invoiced costs
- Avoided premature, full settlement on a complex claim before accountability was established
- Strengthened the insurer's hand in the ongoing cost discussion with the provider